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doi:10.1016/j.jtcvs.2007.08.047bjective: Marfan syndrome is a systemic connective tissue disorder cause
utations in the fibrillin-1 gene. It was originally believed that Marfan syn
esults exclusively from the production of abnormal fibrillin-1 that leads to 
urally weaker connective tissue when incorporated into the extracellular m
his effect seemed to explain many of the clinical features of Marfan syn
ncluding aortic root dilatation and acute aortic dissection, which represent the
auses of morbidity and mortality in Marfan syndrome.
ethods: Recent molecular studies, most based on genetically defined m
odels of Marfan syndrome, have challenged this paradigm. These studies 
ished the critical contribution of fibrillin-1 haploinsufficiency and dysregu
ransforming growth factor-beta signaling to disease progression.
esults: It seems that many manifestations of Marfan syndrome are less rela
 primary structural deficiency of the tissues than to altered morphogeneti
omeostatic programs that are induced by altered transforming growth factor
ignaling. Most important, transforming growth factor-beta antagonism, thro
ransforming growth factor-beta neutralizing antibodies or losartan (an angiote
I type 1 receptor antagonist), has been shown to prevent and possibly revers
oot dilatation, mitral valve prolapse, lung disease, and skeletal muscle dysfun
n a mouse model of Marfan syndrome.
onclusion: There are indicators that losartan, a drug widely used to treat a
ypertension in humans, offers the first potential for primary prevention of c
anifestations in Marfan syndrome.
arfan syndrome (MFS) is a systemic connective tissue disorder 
affects 1 in 5000 individuals.1 It is inherited as an autosomal domin
trait and displays a variety of clinical manifestations in the o
usculoskeletal, and cardiovascular systems. Aortic root aneurysm and subseq
ortic dissection are the leading cause of morbidity and mortality in those with
he majority of fatal events occur in untreated patients in early adult life.2 There-
ore, early diagnosis and advances in surgical treatment, in particular the B
rocedure and more recently the valve-sparing procedure, have significantly
roved life expectancy in MFS.3 A commonly used medical therapy is be
drenergic blockade; however, its efficacy in slowing the aortic root growt
reventing aortic dissection remains controversial.4 Recent advances in understand
ng the complex molecular pathogenesis of MFS have challenged the definit
FS as a structural disorder of the connective tissue. Several studies showe
FS is more a developmental abnormality with broad and complex effects 
orphogenesis and function of multiple organ systems.5-8 Such findings present 
ar more optimistic outlook for patients with MFS, in both pre- and postop
tates, because there is the potential to modify the progression of the disease. A
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CSPecent study showed the efficacy of such therapeutic strat-
gies in a mouse model of MFS.7 In this review, we d-
cribe the most recent progress in understanding the molec-
lar pathogenesis of MFS and discuss its possible clinical
mplications.
enetics of Marfan syndrome
FS is caused by mutations in the gene encoding fibrillin-1
Fbn1). Most mutations in fibrillin-1 occur within repeated
pidermal growth factor-like domains, many disrupting one
f the cysteine residues that interact via disulfide linkage
nd determine ternary structure or amino acid residues
ffecting calcium binding.9,10 Such perturbations lead t
nhanced proteolytic degradation and malfunction of fibril-
in-1. To date, more than 800 mutations in Fbn1 have been
eported in individuals with MFS; however, most families
ith MFS have private mutations.11 Fibrillin-1, a 350-kD
lycoprotein, is a principal component of the extracellular
atrix microfibril.12 Fibrillin-rich microfibrils are present 
ll tissues with clinical manifestations of MFS, for example,
he ocular system, aortic root, and musculoskeletal system.
FS was originally believed to result from the production
f mutant fibrillin-1 that results in structurally weaker con-
ective tissue when incorporated into the microfibrils. This
dverse effect seemed to explain many of the typical clinical
henotypes of MFS, including aortic root dilatation, aortic
issection, lens dislocation, and joint laxity. However, it did
ot fully explain all disease manifestations associated with
FS. For example, why would a weakness in the structure
f the connective tissue lead to bone overgrowth, facial
eatures of MFS, thickening of the heart valves, or low
uscle mass or fat stores? Recent studies, mainly based on
he creation and analysis of genetically engineered mouse
odels, revealed new and promising insights into the com-
lex pathogenesis of MFS.
ouse models of Marfan syndrome
everal mouse models with different mutations in the Fbn1
ene have been developed.13,14 Many of these mouse lin
isplay typical manifestations of MFS, including aortic root
neurysm and subsequent aortic dissection, mitral valve
hickening and prolapse, lung emphysema, and long-bone
vergrowth. First insights into the pathogenesis of MFS
ame from a mouse strain with a mutant allele producing
Abbreviations and Acronyms
AT1  angiotensin II type 1 receptor
AT2  angiotensin II type 2 receptor
MFSMarfan syndrome
TGF transforming growth factortructurally normal fibrillin-1 protein, but at 15% of the d
90 The Journal of Thoracic and Cardiovascular Surgery ● Febrormal level.15 Heterozygous mice showed no abnorma-
ies throughout life, whereas homozygous mice died of
ortic dissection between 3 and 6 months of age. Histologic
nalyses revealed that these mice had a normal content and
rchitecture of elastic fibers at birth. The first detectable
hange in the aortic media was the absence of connecting
laments, which are bundles of microfibrils that connect
lastic fibers to adjacent cells.16 The loss of these conne-
ions between vascular smooth muscle cells and elastic
bers is associated with increased secretion of extracellular
atrix proteins and matrix-degrading enzymes, including
atrix metalloproteinases 2 and 9. Later events, including
ncreased elastolysis and the recruitment of inflammatory
ells, lead to structural collapse of the aortic wall, aortic root
ilatation, and subsequent aortic dissection.17,18 Concordant
hanges were found in aortic root specimens from patients
ith MFS.19 Judge and colleagues6 found that transgeni
verexpression of fibrillin-1 harboring a missense mutation,
n the context of 2 normal Fbn1 genes, was insufficient to
roduce clinical features of MFS in mice. In contrast, mice
eterozygous for a comparable Fbn1 missense mutation
howed aortic changes similar to those seen in other mouse
ines and people with MFS.6 These data suggest that 
ecrease in the amount of normal fibrillin-1, independent of
he production of mutant protein, plays a critical role in
he pathogenesis of MFS. Matyas and colleagues20 reached
imilar conclusions through human genetic studies.
utchinson and colleagues21 described a family with MF
n whom phenotypic severity correlated inversely with the
xpression level of non-mutant fibrillin-1. These data raised
he possibility that boosting fibrillin-1 expression in patients
ith MFS could be a therapeutic strategy.
egulatory role of fibrillin-1 and transforming
rowth factor-beta
ecent studies showed that extracellular microfibrils con-
aining fibrillin-1 not only have an important structural
unction but also interact with and regulate the transforming
rowth factor (TGF)-beta family of growth factors. Fibril-
in-1 shares a high degree of homology with the latent
GF-beta binding proteins.22 TGF-beta is secreted in t
ontext of a large latent complex that includes 1 of 3 latent
GF-beta–binding proteins. The latent TGF-beta–binding
rotein component of the large latent complex targets the
omplex to the matrix and interacts directly with fibrillin-1.
hese findings led to the hypothesis that fibrillin-1 may
articipate in the regulation of TGF-beta signaling, with
nown influences on cellular proliferation, differentiation,
ynthetic repertoire, and survival in a variety of cell types.
eptune and colleagues5 revealed such an interaction wh
nvestigating lung tissue from newborn mice deficient in
brillin-1. These mice showed a widening in the distal
irspaces at birth with no evidence of inflammation or
estruction. Therefore, they hypothesized that such lung
uary 2008
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Pesions may be due to primary failure of alveolar septation
uring development, as opposed to simple mechanical fail-
re of a structurally deficient tissue.5 Similar pulmonary
esions have been reported in patients with MFS for years
ut were attributed to the effects of increased physiologic
tress acting on a “weak” tissue. Neptune and colleagues
urther revealed that changes in the lung tissue were asso-
iated with excess free TGF-beta and increased intracellular
GF-beta signaling. Most important, prenatal administra-
ion of TGF-beta–neutralizing antibodies significantly re-
uced TGF-beta activity in the tissue and resulted in a
ose-dependent increase in alveolar septation.5 These find-
ngs suggested that TGF-beta has a crucial role in regulating
lveolar septation and that up-regulation of growth factor
ctivity may contribute to disease progression in MFS.
eptune and colleagues hypothesized that a similar patho-
enetic mechanism could underlie other manifestations of
FS. Ng and colleagues23 addressed changes in mitra
alves from mice deficient in fibrillin-1 and revealed post-
atally acquired alterations, including an increase in valve
ength and thickness. These findings correlated with in-
reased cell proliferation, increased collagen production,
ecreased apoptosis in valve leaflets, and excessive TGF-
eta activation and TGF-beta signaling. Again, prenatal
dministration of TGF-beta–neutralizing antibodies led to a
ignificant reduction in TGF-beta activity and improved
ostnatal valve architecture.
ortic root aneurysm and effect of losartan
ice heterozygous for a mutant Fbn1 allele (C1039G/)
evelop aortic root dilatation as early as 2 weeks of age with
rogression throughout life.6 The aortic wall in young Fbn1
ice is already thickened, and elastic fibers are fragmented
nd disarrayed.7 Furthermore, there is excessive free TG
eta and TGF-beta signaling in the aortic root tissue, which
s also found in aortic specimens from patients with M7
abashi and colleagues7 hypothesized that TGF-beta ma
lay a causal role in aortic root dilatation, as previously
hown for lung lesions and mitral valve changes in MFS.
ostnatal treatment of fibrillin-1–deficient mice with TGF-
eta neutralizing antibody led to a reduction in TGF-beta
ignaling in the aortic tissue and significantly reduced elas-
ic fiber fragmentation, thickening of the aortic wall, and
ortic root growth.7 Taken together, the data showed th
ncreased TGF-beta signaling contributes to the process of
ortic root dilatation in MFS and that TGF-beta antagonism
ay represent a productive treatment strategy. Unfortu-
ately, the application of TGF-beta–neutralizing antibodies
n patients with MFS is not yet practical. Losartan, an
ngiotensin II type 1 receptor (AT1) antagonist, came to
ttention because of its known effect in antagonizing TGF-
eta in human and animal models of chronic renal insuffi-
iency and cardiomyopathy.24,25 Losartan is a Food and o
The Journal of Thoracicrug Administration-approved medication and is widely
sed medication to decrease blood pressure, a desirable
ffect in individuals with MFS and aortic root aneurysm.
abashi and colleagues7 undertook a blinded randomize
tudy comparing the efficacy of losartan with propranolol,
hich is representative of beta-blocking agents widely used
n patients with MFS, and placebo. The doses of 
lockade and losartan were titrated to achieve a comparable
lood pressure response. Treatment was started beginning at
weeks, after echocardiographic documentation of aortic
oot dilatation. Fibrillin-1–deficient mice treated with pro-
ranolol showed a reduction in the aortic root growth rate
uring a 6-month period compared with the placebo mice;
owever, the growth rate was still significantly greater than
n wild-type mice.7 However, mice treated with losart
ould not be distinguished from wild-type mice by any
arameter, including absolute aortic root size, aortic root
rowth rate, aortic wall thickness, or histologic architecture
Figures 1 and 2).7 Habashi and colleagues7 concluded that
ropranolol may diminish the aortic root growth in MFS but
oes not prevent progressive deterioration of the aortic wall,
hich corresponds to clinical observations in patients with
FS. Most important, losartan maintained the aortic wall
tructure in Fbn1 mice and fully prevented aortic root
ilatation. One could argue that losartan may achieve a
uperior protection over propranolol by virtue of increased
lunting of the hemodynamic shear stress on the aortic root.
owever, this was not the case because doses of losartan
nd propranolol were titrated to achieve comparable hemo-
ynamic effects, and isolated antagonism of TGF-beta with
eutralizing antibody provided similar protection. In addi-
ion, losartan antagonized TGF-beta in the aortic wall, an
vent seen in mice treated with TGF-beta–neutralizing an-
ibody but not in mice treated with propranolol, and further
mproved manifestations of MFS in the lungs and skel-
tal muscle, which could not be related to altered
emodynamics.7
The mechanisms through which AT1 blockade antago-
izes TGF-beta in the aortic wall are not known in detail.
verett and colleagues26 showed that signaling through t
T1 receptor increases expression of TGF-beta ligands and
eceptors. AT1 signaling also stimulates the proliferation of
ascular smooth muscle cells and vessel-wall fibrosis, al-
hough this may depend on the specific vascular segme27
ecent work from Daugherty and colleagues28 showed that
ignaling through the angiotensin II type 2 receptor (AT2)
ntagonizes many of the effects promoted by AT1 signaling
n the formation of abdominal aortic aneurysm. Indeed, the
se of a selective AT2 blocker increased both the incidence
nd the severity of abdominal aortic aneurysms in ApoE
ull mice after angiotensin II infusion, whereas AT1 block-
de prevented aneurysms. Therefore, selective AT1 antag-
nism, as achieved with losartan, may be preferable to
and Cardiovascular Surgery ● Volume 135, Number 2 391
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CSPual AT1/AT2 blockade as achieved with angiotensin-
onverting enzyme inhibitors. However, the positive effect
f losartan on TGF-beta expression may also depend on a
ariety of unknown feedback and signal-cascade
echanisms.
hould we now treat patients who have Marfan
yndrome with losartan?
he current data indicate that patients with MFS are likely
o benefit from being treated with losartan. As such, it may
e tempting to treat all patients who have MFS with losar-
an, given the safety profile of this Food and Drug
dministration-approved medication. However, we believe
hat a cautious approach is needed because data from Fbn1-
argeted mice, although promising, are preliminary. More
tudies are needed to address important questions. For ex-
mple, will the losartan effect be consistent and significantly
etter than that achieved with a beta-blocker over the long
erm? Will there be unanticipated side effects in patients
Figure 1. Inspection of ascending aortic dimension (ar
(A) and Fbn1 (C1039G/) mice treated prenatally with
(A–F)  4 mm. From Habashi JP, Judge DP, Holm TM
antagonist, prevents aortic aneurysm in a mouse mode
with permission from the American Association for thith MFS? What is the consequence of stopping losartan? b
92 The Journal of Thoracic and Cardiovascular Surgery ● Febrhis is an important question given the contraindication to
he use of angiotensin receptor blockers during pregnancy.
tudies addressing the efficacy of beta-blockade in MFS
ave concluded that the therapy is successful in a subset of
ndividuals.4,29 Overall, medicated patients showed slow
ortic root growth, fewer cardiovascular end points, and
mproved survival. Such therapeutic benefit has been ob-
erved in all age groups, including young children. It is
mportant to point out, however, that beta-blockade does not
top or reverse aortic root dilatation but typically slows the
ortic root growth in patients with MFS. Beta-blockers have
o effect on other clinical manifestations of MFS, and 10%
o 20% of patients are intolerant to beta-blockers because of
sthma, depression, or fatigue.1 In contrast, losartan ma
ffer the first potential treatment for the primary prevention
f phenotypes associated with MFS, including life-threat-
ning aortic root dilatation and aortic dissection, mitral
alve changes, lung disease, and skeletal myopathy. A mul-
icenter randomized clinical trial comparing losartan with
eads) after latex injection in representative wild-type
ebo (B), propranolol (C), or losartan (D–F). Scale bars
hn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1
Marfan syndrome. Science. 2006;312:117-21. Reprinted
vancement of Science.rowh
plac
, Co
l of
e Adeta-blocker therapy in children and young adults with MFS
uary 2008
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Pnd aortic aneurysm has recently been started (coordinated
hrough the Pediatric Heart Network of the National Heart,
ung, and Blood Institute of the National Institutes of
ealth) and will aim to answer many of these questions,
ncluding the long-term efficacy of losartan and possible
ide effects in this particular subset of patients. The study
ims to recruit at least 600 patients in a 3-year time period.
t is also critical to determine whether there is the potential
o reverse damage, for example, aortic root dilatation and
itral valve changes associated with MFS. Early indicators
n mouse models suggest that this may be true. Less can be
aid about the potential for losartan therapy to protect seg-
ents of the aorta that have already been damaged by
hronic dissection. Will antagonizing the profibrotic and/or
nti-inflammatory effects of TGF-beta limit the quality of
car formation or promote further destruction through in-
ammatory cell recruitment, or will it limit disease progres-
ion by decreasing the expression of matrix-degrading en-
ymes, among other potential beneficial effects? As people
ith MFS are living longer, a later predisposition for dila-
ation and dissection of other aortic segments, prominently
he proximal descending aorta, is becoming apparent. Can
e expect a similar therapeutic effect of losartan? Clearly,
ore research is needed to address these important issues. s
The Journal of ThoracicUp-regulation of TGF-beta seems to be a final common
athway for aortic aneurysm in many disease states. There-
ore, if losartan is effective in treating clinical manifesta-
ions in patients with MFS, this could prove a valid treat-
ent strategy for other aneurysm syndromes, including
atients with TGF-beta receptor mutations (Loeys–Dietz
yndrome). This would be particularly important because
oeys–Dietz syndrome is associated with aggressive vascu-
ar disease, including aneurysms throughout the arterial tree
nd dissection at young ages and at relatively small vascular
imensions that do not confer risk in MFS.30,31 Despite the
romising nature of the results presented in this review, it
emains clear that caution and careful study are needed to
roductively transfer these data from bench to bedside. Such
fforts may be rewarded by an improved management of
atients with MFS. If and how these promising findings will
nfluence future cardiovascular surgical practice remain to
e elucidated.
Peter Matt thanks the Swiss National Foundation, the Novartis
oundation, and the Hippocrate Foundation Basel for financial
upport. The work presented in this review was funded by the
ational Institutes of Health, the Howard Hughes Medical Insti-
ute, the William S. Smilow Center for Marfan Syndrome Re-
Figure 2. Postnatal treatment with lo-
sartan, propranolol, or placebo. Ver-
hoeff–van Gieson staining: Elastic la-
mellae are intact and the aortic wall is
of normal thickness in wild-type and
losartan-treated Fbn1 (C1039G/)
mice. In contrast, placebo- and pro-
pranolol-treated Fbn1 mice have frag-
mented and disarrayed elastic fibers,
and the aortic wall is thickened.earch, and the National Marfan Foundation.
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